INDUSTRY OVERVIEW
The Precision Oncology is Growing at 7.50% and is expected to reach 60Billion by 2032. Below mentioned are some of the dynamics shaping the Precision Oncology.Precision Oncology Market Size in (USD Billion) CAGR Growth Rate 7.50%
| Study Period | 2020-2032 |
| Market Size (2024): | 30Billion |
| Market Size (2032): | 60Billion |
| CAGR (2024 - 2032): | 7.50% |
| Fastest Growing Region | Asia-Pacific |
| Dominating Region | North America |
www.htfmarketinsights.com
Precision oncology is a medical approach that customizes cancer treatment based on individual genetic, environmental, and lifestyle factors. It uses biomarkers and genomic profiling to tailor therapies for more effective and less toxic cancer treatments. This approach allows for targeted therapies and immunotherapies that improve patient outcomes and reduce side effects. It is transforming oncology by focusing on personalized medicine and integrating advanced diagnostics and treatment monitoring tools. Precision oncology is a dynamic, data-driven field that continually evolves with scientific breakthroughs and clinical research.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Regulatory Landscape
- Regulatory frameworks require companion diagnostics, clinical trial data, and reimbursement approvals. Data privacy and ethical considerations influence implementation.
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Rising Cancer Incidence
- technological Advances
- personalized Medicine Demand
- increasing Awareness
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- High Cost Of Treatments
- regulatory Hurdles
- data Privacy
- reimbursement Limitations
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Integration of AI
- liquid biopsy adoption
- immunotherapy growth
- multi-omics data use
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Expansion In Emerging Markets
- AI-powered Diagnostics
- companion Diagnostics Growth
- precision Prevention
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Biomarker Testing
- Genomic Profiling
- Liquid Biopsy
- Targeted Therapy
Precision Oncology Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Cancer Diagnostics
- Treatment Monitoring
- Drug Development
- Personalized Treatment
- Prognosis
Precision Oncology Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia-Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia-Pacific
![Asia-Pacific dominates Precision Oncology Market [2020 to 2024]](https://www.htfmarketinsights.com/assets_n/img/region/continent/asia_pacific_wn.png)
Dominating Region
North America
![North America dominates Precision Oncology Market [2020 to 2024]](https://www.htfmarketinsights.com/assets_n/img/region/continent/north_america_wn.png)
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Roche (Switzerland)
- Novartis (Switz.)
- Foundation Med (USA)
- Guardant Health (USA)
- Illumina (USA)
- Qiagen (Germany)
- Thermo Fisher (USA)
- AstraZeneca (UK)
- Pfizer (USA)
- Bristol-Myers Squibb (USA)
- Merck (USA)
- Agilent (USA)
- Bio-Rad (USA)
- NanoString (USA)
Precision Oncology Market Segmentation by Players
www.htfmarketinsights.com
Regional Analysis
- Strong focus in North America, Europe, and Asia-Pacific pharma hubs.
Regulatory Landscape
- Regulatory frameworks require companion diagnostics, clinical trial data, and reimbursement approvals. Data privacy and ethical considerations influence implementation.
Patent Analysis
- Patents cover targeted therapies, biomarkers, and diagnostic technologies.
Investment and Funding Scenario
- Significant investment from pharma, biotech, and diagnostics companies.
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2024 |
|
Based Year Market Size (2023) |
30Billion |
|
Historical Period |
2020 to 2024 |
|
CAGR (2024 to 2032) |
7.50% |
|
Forecast Period |
2024 to 2032 |
|
Forecasted Period Market Size (2032) |
60Billion |
|
Scope of the Report |
Segmentation by Type Biomarker Testing,Genomic Profiling,Liquid Biopsy,Targeted Therapy, Segmentation by Application Cancer Diagnostics,Treatment Monitoring,Drug Development,Personalized Treatment,Prognosis, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Roche (Switzerland),Novartis (Switz.),Foundation Med (USA),Guardant Health (USA),Illumina (USA),Qiagen (Germany),Thermo Fisher (USA),AstraZeneca (UK),Pfizer (USA),Bristol-Myers Squibb (USA),Merck (USA),Agilent (USA),Bio-Rad (USA),NanoString (USA) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Precision Oncology - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Precision Oncology Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Precision Oncology Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Precision Oncology Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Rising cancer incidence
- 3.1.2 technological advances
- 3.1.3 personalized medicine demand
- 3.1.4 increasing awareness
-
3.2 Available Opportunities
- 3.2.1 Expansion in emerging markets
- 3.2.2 AI-powered diagnostics
- 3.2.3 companion diagnostics
-
3.3 Influencing Trends
- 3.3.1 Integration of AI
- 3.3.2 liquid biopsy adoption
- 3.3.3 immunotherapy growth
- 3.3.4 multi-omics d
-
3.4 Challenges
- 3.4.1 High cost of treatments
- 3.4.2 regulatory hurdles
- 3.4.3 data privacy
- 3.4.4 reimbursement limit
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Precision Oncology Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Precision Oncology Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Precision Oncology : Competition Benchmarking & Performance Evaluation
- 5.1 Global Precision Oncology Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Precision Oncology Revenue 2024
- 5.3 Global Precision Oncology Sales Volume by Manufacturers (2024)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 Strategic Group Analysis
- 5.6 5C’s Analysis
Chapter 6: Global Precision Oncology Market: Company Profiles
- 6.1 Roche (Switzerland)
- 6.1.1 Roche (Switzerland) Company Overview
- 6.1.2 Roche (Switzerland) Product/Service Portfolio & Specifications
- 6.1.3 Roche (Switzerland) Key Financial Metrics
- 6.1.4 Roche (Switzerland) SWOT Analysis
- 6.1.5 Roche (Switzerland) Development Activities
- 6.2 Novartis (Switz.)
- 6.3 Foundation Med (USA)
- 6.4 Guardant Health (USA)
- 6.5 Illumina (USA)
- 6.6 Qiagen (Germany)
- 6.7 Thermo Fisher (USA)
- 6.8 AstraZeneca (UK)
- 6.9 Pfizer (USA)
- 6.10 Bristol-Myers Squibb (USA)
- 6.11 Merck (USA)
- 6.12 Agilent (USA)
- 6.13 Bio-Rad (USA)
- 6.14 NanoString (USA)
- 6.15 Myriad Genetics (USA)
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Precision Oncology by Type & Application (2020-2032)
-
7.1 Global Precision Oncology Market Revenue Analysis (USD Million) by Type (2020-2024)
- 7.1.1 Biomarker Testing
- 7.1.2 Genomic Profiling
- 7.1.3 Liquid Biopsy
- 7.1.4 Targeted Therapy
- 7.1.5 Immunotherapy
-
7.2 Global Precision Oncology Market Revenue Analysis (USD Million) by Application (2020-2024)
- 7.2.1 Cancer Diagnostics
- 7.2.2 Treatment Monitoring
- 7.2.3 Drug Development
- 7.2.4 Personalized Treatment
- 7.2.5 Prognosis
- 7.3 Global Precision Oncology Market Revenue Analysis (USD Million) by Type (2024-2032)
- 7.4 Global Precision Oncology Market Revenue Analysis (USD Million) by Application (2024-2032)
Chapter 8 : North America Precision Oncology Market Breakdown by Country, Type & Application
- 8.1 North America Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 8.2.1 Biomarker Testing
- 8.2.2 Genomic Profiling
- 8.2.3 Liquid Biopsy
- 8.2.4 Targeted Therapy
- 8.2.5 Immunotherapy
-
8.3 North America Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 8.3.1 Cancer Diagnostics
- 8.3.2 Treatment Monitoring
- 8.3.3 Drug Development
- 8.3.4 Personalized Treatment
- 8.3.5 Prognosis
- 8.4 North America Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 8.5 North America Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 8.6 North America Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Precision Oncology Market Breakdown by Country, Type & Application
- 9.1 LATAM Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 9.2.1 Biomarker Testing
- 9.2.2 Genomic Profiling
- 9.2.3 Liquid Biopsy
- 9.2.4 Targeted Therapy
- 9.2.5 Immunotherapy
-
9.3 LATAM Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 9.3.1 Cancer Diagnostics
- 9.3.2 Treatment Monitoring
- 9.3.3 Drug Development
- 9.3.4 Personalized Treatment
- 9.3.5 Prognosis
- 9.4 LATAM Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 9.5 LATAM Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 9.6 LATAM Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 10 : West Europe Precision Oncology Market Breakdown by Country, Type & Application
- 10.1 West Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 10.2.1 Biomarker Testing
- 10.2.2 Genomic Profiling
- 10.2.3 Liquid Biopsy
- 10.2.4 Targeted Therapy
- 10.2.5 Immunotherapy
-
10.3 West Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 10.3.1 Cancer Diagnostics
- 10.3.2 Treatment Monitoring
- 10.3.3 Drug Development
- 10.3.4 Personalized Treatment
- 10.3.5 Prognosis
- 10.4 West Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 10.5 West Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 10.6 West Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 11 : Central & Eastern Europe Precision Oncology Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 11.2.1 Biomarker Testing
- 11.2.2 Genomic Profiling
- 11.2.3 Liquid Biopsy
- 11.2.4 Targeted Therapy
- 11.2.5 Immunotherapy
-
11.3 Central & Eastern Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 11.3.1 Cancer Diagnostics
- 11.3.2 Treatment Monitoring
- 11.3.3 Drug Development
- 11.3.4 Personalized Treatment
- 11.3.5 Prognosis
- 11.4 Central & Eastern Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 11.5 Central & Eastern Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 11.6 Central & Eastern Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 12 : Northern Europe Precision Oncology Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 12.2.1 Biomarker Testing
- 12.2.2 Genomic Profiling
- 12.2.3 Liquid Biopsy
- 12.2.4 Targeted Therapy
- 12.2.5 Immunotherapy
-
12.3 Northern Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 12.3.1 Cancer Diagnostics
- 12.3.2 Treatment Monitoring
- 12.3.3 Drug Development
- 12.3.4 Personalized Treatment
- 12.3.5 Prognosis
- 12.4 Northern Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 12.5 Northern Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 12.6 Northern Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 13 : Southern Europe Precision Oncology Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 13.2.1 Biomarker Testing
- 13.2.2 Genomic Profiling
- 13.2.3 Liquid Biopsy
- 13.2.4 Targeted Therapy
- 13.2.5 Immunotherapy
-
13.3 Southern Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 13.3.1 Cancer Diagnostics
- 13.3.2 Treatment Monitoring
- 13.3.3 Drug Development
- 13.3.4 Personalized Treatment
- 13.3.5 Prognosis
- 13.4 Southern Europe Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 13.5 Southern Europe Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 13.6 Southern Europe Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 14 : East Asia Precision Oncology Market Breakdown by Country, Type & Application
- 14.1 East Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 14.2.1 Biomarker Testing
- 14.2.2 Genomic Profiling
- 14.2.3 Liquid Biopsy
- 14.2.4 Targeted Therapy
- 14.2.5 Immunotherapy
-
14.3 East Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 14.3.1 Cancer Diagnostics
- 14.3.2 Treatment Monitoring
- 14.3.3 Drug Development
- 14.3.4 Personalized Treatment
- 14.3.5 Prognosis
- 14.4 East Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 14.5 East Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 14.6 East Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 15 : Southeast Asia Precision Oncology Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 15.2.1 Biomarker Testing
- 15.2.2 Genomic Profiling
- 15.2.3 Liquid Biopsy
- 15.2.4 Targeted Therapy
- 15.2.5 Immunotherapy
-
15.3 Southeast Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 15.3.1 Cancer Diagnostics
- 15.3.2 Treatment Monitoring
- 15.3.3 Drug Development
- 15.3.4 Personalized Treatment
- 15.3.5 Prognosis
- 15.4 Southeast Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 15.5 Southeast Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 15.6 Southeast Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 16 : South Asia Precision Oncology Market Breakdown by Country, Type & Application
- 16.1 South Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 16.2.1 Biomarker Testing
- 16.2.2 Genomic Profiling
- 16.2.3 Liquid Biopsy
- 16.2.4 Targeted Therapy
- 16.2.5 Immunotherapy
-
16.3 South Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 16.3.1 Cancer Diagnostics
- 16.3.2 Treatment Monitoring
- 16.3.3 Drug Development
- 16.3.4 Personalized Treatment
- 16.3.5 Prognosis
- 16.4 South Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 16.5 South Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 16.6 South Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 17 : Central Asia Precision Oncology Market Breakdown by Country, Type & Application
- 17.1 Central Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 17.2.1 Biomarker Testing
- 17.2.2 Genomic Profiling
- 17.2.3 Liquid Biopsy
- 17.2.4 Targeted Therapy
- 17.2.5 Immunotherapy
-
17.3 Central Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 17.3.1 Cancer Diagnostics
- 17.3.2 Treatment Monitoring
- 17.3.3 Drug Development
- 17.3.4 Personalized Treatment
- 17.3.5 Prognosis
- 17.4 Central Asia Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 17.5 Central Asia Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 17.6 Central Asia Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 18 : Oceania Precision Oncology Market Breakdown by Country, Type & Application
- 18.1 Oceania Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 18.2.1 Biomarker Testing
- 18.2.2 Genomic Profiling
- 18.2.3 Liquid Biopsy
- 18.2.4 Targeted Therapy
- 18.2.5 Immunotherapy
-
18.3 Oceania Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 18.3.1 Cancer Diagnostics
- 18.3.2 Treatment Monitoring
- 18.3.3 Drug Development
- 18.3.4 Personalized Treatment
- 18.3.5 Prognosis
- 18.4 Oceania Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 18.5 Oceania Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 18.6 Oceania Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 19 : MEA Precision Oncology Market Breakdown by Country, Type & Application
- 19.1 MEA Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 19.2.1 Biomarker Testing
- 19.2.2 Genomic Profiling
- 19.2.3 Liquid Biopsy
- 19.2.4 Targeted Therapy
- 19.2.5 Immunotherapy
-
19.3 MEA Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 19.3.1 Cancer Diagnostics
- 19.3.2 Treatment Monitoring
- 19.3.3 Drug Development
- 19.3.4 Personalized Treatment
- 19.3.5 Prognosis
- 19.4 MEA Precision Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 19.5 MEA Precision Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 19.6 MEA Precision Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Global Precision Oncology market size surpassed 30 Billion in 2024 and will expand at a CAGR of 7.50% between 2024 and 2032.
The Precision Oncology Market is growing at a CAGR of 7.50% over the forecasted period 2024 - 2032.
Some of the prominent trends that are influencing and driving the growth of Global Precision Oncology Market are Integration Of AI,liquid Biopsy Adoption,immunotherapy Growth,multi-omics Data Use,telemedicine For Oncology
- Rising Cancer Incidence
- technological Advances
- personalized Medicine Demand
- increasing Awareness
- favorable Reimbursement Policies
Business transformation in Precision Oncology Market has taken hold due to the confluence of several important triggers, some of them are High Cost Of Treatments,regulatory Hurdles,data Privacy,reimbursement Limitations,complex Biomarker Validation.
Some of the opportunities that Analyst at HTF MI have identified in Precision Oncology Market are:
- Expansion In Emerging Markets
- AI-powered Diagnostics
- companion Diagnostics Growth
- precision Prevention
- real-world Data Use
Roche (Switzerland),Novartis (Switz.),Foundation Med (USA),Guardant Health (USA),Illumina (USA),Qiagen (Germany),Thermo Fisher (USA),AstraZeneca (UK),Pfizer (USA),Bristol-Myers Squibb (USA),Merck (USA),Agilent (USA),Bio-Rad (USA),NanoString (USA),Myriad Genetics (USA) etc are the main players listed in the Global Precision Oncology Market Study.
The Global Precision Oncology Market Study is Broken down by applications such as Cancer Diagnostics,Treatment Monitoring,Drug Development,Personalized Treatment,Prognosis.
The Global Precision Oncology Market Study is segmented by Biomarker Testing,Genomic Profiling,Liquid Biopsy,Targeted Therapy,Immunotherapy.
The Global Precision Oncology Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2020 - 2024; Base year: 2024; Forecast period: 2025 to 2032
Precision oncology is a medical approach that customizes cancer treatment based on individual genetic, environmental, and lifestyle factors. It uses biomarkers and genomic profiling to tailor therapies for more effective and less toxic cancer treatments. This approach allows for targeted therapies and immunotherapies that improve patient outcomes and reduce side effects. It is transforming oncology by focusing on personalized medicine and integrating advanced diagnostics and treatment monitoring tools. Precision oncology is a dynamic, data-driven field that continually evolves with scientific breakthroughs and clinical research.
